Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Utidelone Plus Capecitabine in Metastatic Breast Cancer
NCT06458413Phase 2Active, not recruiting
- Sponsor
- Min-Yan Pharmaceutical
- Start
- Jun 2024
- Primary completion
- Jul 2026
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
A Phase 2 trial of utidelone in breast cancer, sponsored by Min-Yan Pharmaceutical. Started Jun 2024; status: active, not recruiting.
02
Drugs
utidelone
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06458413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06458413.